Kura Oncology, Inc.
KURA
$9.22
-$0.52-5.34%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 29.47% | -67.83% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.47% | -67.83% | -- | -- | -- |
| Cost of Revenue | 17.07% | 23.34% | 62.83% | 58.04% | 54.33% |
| Gross Profit | -12.89% | -3,016.40% | -13.08% | -19.56% | -15.43% |
| SG&A Expenses | 38.19% | 62.60% | 80.64% | 50.92% | 25.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.19% | 35.72% | 68.24% | 55.94% | 44.73% |
| Operating Income | -21.82% | -284.18% | -33.59% | -28.83% | -18.82% |
| Income Before Tax | -28.18% | -370.54% | -36.23% | -30.07% | -15.50% |
| Income Tax Expenses | -96.46% | -96.48% | -- | -- | -- |
| Earnings from Continuing Operations | -27.69% | -321.50% | -36.23% | -30.07% | -15.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.69% | -321.50% | -36.23% | -30.07% | -15.96% |
| EBIT | -21.82% | -284.18% | -33.59% | -28.83% | -18.82% |
| EBITDA | -21.72% | -285.89% | -33.78% | -28.90% | -18.89% |
| EPS Basic | -25.97% | -317.19% | -35.14% | -28.65% | -11.30% |
| Normalized Basic EPS | -26.45% | -191.68% | -35.13% | -28.66% | -10.87% |
| EPS Diluted | -25.97% | -317.19% | -35.14% | -28.65% | -11.30% |
| Normalized Diluted EPS | -26.45% | -191.68% | -35.13% | -28.66% | -10.87% |
| Average Basic Shares Outstanding | 1.37% | 1.05% | 0.80% | 1.10% | 4.18% |
| Average Diluted Shares Outstanding | 1.37% | 1.05% | 0.80% | 1.10% | 4.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |